AIM
LGND icon

Advantage Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Advantage Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-155
Closed -$12K – 936
2016
Q2 		$12K Buy
155
+57
+58% +$4.23K 0.01% 560
2016
Q1 		$7K Buy
+98
New +$5.96K ﹤0.01% 628
2015
Q1 		– Sell
-96
Closed -$3K – 871
2014
Q4 		$3K Buy
+96
New +$3.12K ﹤0.01% 671

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Advantage Investment Management's LGND Position: Q3 2016 in Review

Advantage Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2016, closing a stake of 155 shares — an estimated $12K sold.

Advantage Investment Management first reported a position in LGND in Q4 2014 and held it in 3 quarters. The position peaked at $12K in Q2 2016. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

  • Advantage Investment Management reported no remaining Ligand Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Advantage Investment Management sold 155 Ligand Pharmaceuticals shares in Q3 2016, an estimated $12K.
  • Advantage Investment Management first reported a position in Ligand Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Advantage Investment Management's Ligand Pharmaceuticals position peaked at $12K in Q2 2016.
  • 259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Advantage Investment Management's 13F filing for Q3 2016, filed 27 Mar 2017.